A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04338269. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC) who experienced radiographic tumor progression during or after Immune Checkpoint Inhibitor (ICI) treatment in the metastatic setting.
Study identification
- NCT ID
- NCT04338269
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 522 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 28, 2020 (Actual)
- Primary completion
- Jan 3, 2023 (Actual)
- Completion
- Mar 24, 2025 (Actual)
- Last update posted
- Mar 19, 2026
2020 – 2025
United States locations
- U.S. sites
- 24
- U.S. states
- 16
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona | Tucson | Arizona | 85724-5030 | — |
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | — |
| UC San Diego Health System | La Jolla | California | 92093 | — |
| UCLA | Los Angeles | California | 90095 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Rocky Mountain Cancer Center - Denver | Littleton | Colorado | 80120 | — |
| Woodlands Medical Specialists, P.A. | Pensacola | Florida | 32503 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland | 21287 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Minnesota Oncology Hematology | Minneapolis | Minnesota | 55404 | — |
| Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley | Las Vegas | Nevada | 89169 | — |
| Memorial Sloan Kettering - Monmouth | Middletown | New Jersey | 07748 | — |
| Memorial Sloan Kettering Bergen | Montvale | New Jersey | 07645 | — |
| New York Oncology Hematology,P.C.-Albany | Albany | New York | 12208 | — |
| Mount Sinai Medical Center | New York | New York | 10029 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Texas Oncology - Central South | Austin | Texas | 78731 | — |
| University Of Utah | Salt Lake City | Utah | 84108 | — |
| Virginia Cancer Specialists - Gainsville | Gainesville | Virginia | 20155 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 111 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04338269, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 19, 2026 · Synced Nov 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.